Pharmather Eyes Commercialization of Parkinson’s Ketamine Treatment

Pharmather is advancing its ketamine-based treatment for Parkinson’s disease as the approval decision date of Aug. 9, 2025, set by the U.S. Food and Drug Administration (FDA) draws closer.

If approved, the company plans to market the product under the brand name Ketarx and expand its use in neurological conditions, including Parkinson’s, where ketamine’s potential to ease symptoms such as tremors and dyskinesia, or involuntary movements, is being actively explored.

“Receiving an approval goal date from the FDA provides a clear line of sight to potential approval and commercialization for our ketamine product,” Fabio Chianelli, Pharmather CEO, said in a company press release.